Initial results from a biomarker-directed phase 2 trial of SY-1425, a potent and selective RAR alpha agonist, in combination with azacitidine in relapsed/refractory acute myeloid leukemia Meeting Abstract
| Authors: | Stein, E. M.; De Botton, S.; Cluzeau, T.; Pigneux, A.; Liesveld, J. L.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Braun, T.; Bixby, D. L.; Roboz, G. J.; Lebon, D.; Heiblig, M.; Kelly, M. J.; Volkert, A.; Zhou, L.; Kang-Fortner, Q.; Roth, D. A.; Peterlin, P. |
| Abstract Title: | Initial results from a biomarker-directed phase 2 trial of SY-1425, a potent and selective RAR alpha agonist, in combination with azacitidine in relapsed/refractory acute myeloid leukemia |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607205603258 |
| DOI: | 10.1182/blood-2020-134602 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 6 -- Source: Wos |
